We are live on ! Find out more
NAMSW icon

NewAmsterdam Pharma Warrant
NAMSW

18 hedge funds and large institutions have $4.73M invested in NewAmsterdam Pharma Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.83% more ownership

Funds ownership: 0% → 1.83% (+1.8%)

0% more funds holding

Funds holding: 18 → 18 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

5% less capital invested

Capital invested by funds: $5M → $4.73M (-$272K)

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
2
Calls
$157K
Puts
–
Net Calls
+$157K
Net Calls Change
+$19K

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$26.8K
2
Walleye Capital
Walleye Capital
New York
+$13.5K
3
CG
Cutler Group
California
+$10.7K
4
Walleye Trading
Walleye Trading
New York
+$7.59K

Top Sellers

Rank Fund Capital Flow
1
ETH
Exos TFP Holdings
New York
-$154K
2
CC
Caxton Corporation
New Jersey
-$40.5K
3
MTCM
Mint Tower Capital Management
Netherlands
-$12K
4
CS
Clear Street
New York
-$8.94K
Name Holding Trade Value Shares
Change 		Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$1.05M – – –
HCM
2
Highbridge Capital Management
New York
$966K – – –
EC
3
EcoR1 Capital
California
$793K – – –
RCM
4
RA Capital Management
Massachusetts
$697K – – –
Ensign Peak Advisors
5
Ensign Peak Advisors
Utah
$314K – – –
BCLSI
6
Bain Capital Life Sciences Investors
Massachusetts
$209K – – –
DM
7
Deerfield Management
New York
$194K – – –
AAA
8
Affinity Asset Advisors
New York
$77.3K – – –
Walleye Capital
9
Walleye Capital
New York
$67.4K +$13.5K +6,272 +24%
WCMNY
10
Westchester Capital Management (New York)
New York
$65.2K – – –
HF
11
HRT Financial
New York
$63K – – –
ETH
12
Exos TFP Holdings
New York
$46.6K -$154K -71,659 -76%
Walleye Trading
13
Walleye Trading
New York
$38.6K +$7.59K +3,528 +24%
PI
14
PEAK6 Investments
Illinois
$35.5K – – –
LCM
15
Laurion Capital Management
New York
$34.8K – – –
CS
16
Clear Street
New York
$28.1K -$8.94K -4,156 -24%
WAM
17
Wolverine Asset Management
Illinois
$26K +$26.8K +12,448 New
VI
18
Vestcor Inc
New Brunswick, Canada
$20K – – –
CG
19
Cutler Group
California
$10K +$10.7K +4,960 New
CC
20
Caxton Corporation
New Jersey
– -$40.5K -21,333 Closed
MTCM
21
Mint Tower Capital Management
Netherlands
– -$12K -6,533 Closed

NAMSW Hedge Fund Activity: Q2 2023 in Review

18 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q2 2023, worth a combined $4.73M — down 5.4% from $5M a quarter earlier.

Fund positioning in NAMSW was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $26.8K. The largest seller was Exos TFP Holdings, cutting an estimated $154K.

  • 18 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $4.73M of NewAmsterdam Pharma Warrant stock for Q2 2023, down 5.4% quarter-over-quarter.
  • 2 funds opened new NewAmsterdam Pharma Warrant positions in Q2 2023 and 2 closed out, a net change of 0 holders.
  • The largest NewAmsterdam Pharma Warrant buyer in Q2 2023 was Wolverine Asset Management, an estimated $26.8K added.
  • The largest NewAmsterdam Pharma Warrant seller in Q2 2023 was Exos TFP Holdings, an estimated $154K sold.

Based on aggregated 13F filings for Q2 2023.